BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $16.30.

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Royal Bank Of Canada restated an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research note on Saturday, September 27th. Evercore ISI reaffirmed an “in-line” rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday. Finally, Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th.

Insider Buying and Selling

In related news, Director Theresa Heggie sold 70,000 shares of the business’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director owned 65,352 shares of the company’s stock, valued at $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp increased its holdings in BioCryst Pharmaceuticals by 8.9% during the 2nd quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock valued at $76,208,000 after purchasing an additional 691,988 shares in the last quarter. Alkeon Capital Management LLC increased its holdings in BioCryst Pharmaceuticals by 1.7% during the 1st quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company’s stock valued at $54,105,000 after purchasing an additional 120,199 shares in the last quarter. Geode Capital Management LLC increased its holdings in BioCryst Pharmaceuticals by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company’s stock valued at $45,296,000 after purchasing an additional 93,973 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in BioCryst Pharmaceuticals by 2,103.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after purchasing an additional 4,084,403 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in BioCryst Pharmaceuticals by 382.6% during the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after purchasing an additional 3,022,769 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Trading Down 2.5%

Shares of BioCryst Pharmaceuticals stock opened at $7.15 on Tuesday. The company’s fifty day simple moving average is $8.11 and its 200-day simple moving average is $8.70. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -39.72, a PEG ratio of 1.44 and a beta of 1.05. BioCryst Pharmaceuticals has a 1 year low of $6.01 and a 1 year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. The business’s revenue for the quarter was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.06) earnings per share. As a group, research analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.